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MATERIALS AND
METHODS
We searched databases that were published in English and Chinese up to September 10, 2014 for
our studies. Eligibility criteria were pre-established. Title, abstract, and full-text screenings were
conducted by 2 authors independently. Discrepancies were resolved by consensus. Quality
assessment of included studies was completed. Meta-analysis was done when appropriate using R,
version 3.1.1 for Windows. Heterogeneity among individual studies was tested using the Cochran
chi-square Q test and quantiﬁed by calculating the I2 index.RESULTS Thirteen of 1278 publications met inclusion criteria and were incorporated into this study. Of 306
patients with preoperative hormone therapy, 25 displayed androgen resistance. Meta-analysis
demonstrated that the random-effects model generates a pooled estimate of 7.14% (95% conﬁ-
dence interval [CI], 3.16%-15.31%), whereas the ﬁxed-effect model provides an estimate of
14.61% (95% CI, 10.00%-20.85%). Heterogeneity among included studies was found above
medium (I2 ¼ 67.1% [95% CI, 41.2%-81.6%]; P ¼ .0003]. After exclusion of the heterogeneity,
both random-effects and ﬁxed-effect models produce a consistent pooled estimate of 6.95% (95%
CI, 0%-47.8%).CONCLUSION We have deﬁned that the prevalence of androgen resistance in hypospadias is 7.14% (95% CI,
3.16%-15.31%). To distinguish isolated hypospadias from patients with androgen insensitivity
syndrome, we recommend that androgen-resistant patients should be speciﬁcally targeted by
molecularly focused diagnosis. Management strategies should include identiﬁcation of mutations
in the androgen receptor gene, timely surgery to repair hypospadias, and long-term follow-up of
sexual function and fertility later in life. UROLOGY 85: 1166e1172, 2015.  2015 Elsevier Inc.ndrogen plays a central role in male external
genital development. Androgen insensitivityAsyndrome is deﬁned as a disorder that has
complete or partial resistance to the biological actions of
androgenic hormones in an XY man or boy who has
normal testis determination and production of age-
appropriate levels of androgenic hormones but has a
function deﬁciency of androgen receptor.1 The patho-
physiological changes of this syndrome depend on the
mechanism and effectiveness of androgenic hormones.
Micropenis, severe hypospadias (perineoscrotal), and atributed equally to this work.
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servedbiﬁd scrotum, although occur in various degrees, are
typical clinical phenotypes of partial androgen insensi-
tivity syndrome. A guidance on how to evaluate partial
androgen insensitivity syndrome and other disorders of
sex development for an infant or an adolescent has been
established,2 but deﬁnitive diagnosis relies on the iden-
tiﬁcation of mutations in the androgen receptor gene that
impede the normal function of androgenic hormones. A
short course of testosterone (25 mg intramuscular injec-
tion monthly for 3 months) or topical dihydrotestoster-
one gel application would be able to determine the
androgenic responsiveness.3
Hypospadias, deﬁned as a malformation of the penis
due to an incomplete development of the ventral part of
the penis, is the second most common congenital
anomaly in men, with a prevalence of about 4-6 in 1000
male births.4 Although the etiology of hypospadias is still
unclear, both genetic and environmental factors are
implicated in the cause.4 Hypospadias is generally an
isolated disease and may also represent one of the clinicalhttp://dx.doi.org/10.1016/j.urology.2015.01.035
0090-4295/15
manifestations of androgen insensitivity syndrome.
Reconstructive surgery is the main treatment of hypo-
spadias when the patients are young and the penis is
small. However, hypospadias repair is frequently associ-
ated with numerous complications including ure-
throcutaneous ﬁstulas, meatal stenosis, urethral strictures,
and scar formation.5,6 To simplify the surgery and
improve the surgical outcome, preoperative hormone
therapy with testosterone, dihydrotestosterone, or human
chorionic gonadotropin in hypospadias with small penises
has been in some clinical practices for decades because it
can temporarily compel phallic growth, which renders the
surgical correction easier, reduces the non-negligible risk
of complications, and improves the functional and
cosmetic results after hypospadias repair.7-14 However,
preoperative hormone therapy has not been ubiquitously
accepted and, in some extent, remained controversial.15
Increasing concerns have been raised over potential
negative effects of preoperative hormone therapy such as
increased erections and pubic hair growth, and acceler-
ated linear height and bone age.7-9,16 In addition, an-
drogens were reported to inhibit wound healing and
increase inﬂammation.17 A recent prospective, non-
randomized study implicated that hypospadias patients
treated with preoperative testosterone might increase the
risk of complications.5
Nevertheless, preoperative hormone therapy in hypo-
spadias has generated signiﬁcant beneﬁts although some
reports have brought up concerns for negative effects.
Thus, it is imperative to increase the beneﬁts and reduce
the costs. It is well known that many hypospadias patients
do not show response to preoperative hormone therapy as
reported in numerous publications. However, the precise
prevalence of androgen resistance in hypospadias is still
obscure. Reliable estimates of the extent of androgen
insensitivity will be essential for the development of clear
and uniform approach to differential diagnosis and
decrease of the costs. Therefore, we conducted a systemic
review and meta-analysis of different individual studies to
synthesize the results from individual studies and assess
clinical androgen insensitivity prevalence in hypospadias
patients treated with preoperative hormone therapy,
aiming to provide reliable information for improving
management strategies of the disease.MATERIALS AND METHODS
Search Strategy and Selection Criteria
We searched PubMed (from 1950 to September 10, 2014),
EMBASE (from 1980 to September 10, 2014), and Chinese
Biological Medicine (from 1978 to September 10, 2014) with the
Medical Subject Heading terms “hypospadias” in combination
with the additional term of “testosterone,” “dihydrotestosterone,”
“chorionic gonadotropin,” or “androgen insensitivity syndrome.”
In addition, the Cochrane library (http://www.cochrane.org) was
searched with the terms of “hypospadias” and “testosterone.”
Furthermore, additional relevant literatures were reviewed from
citations in the retrieved articles.UROLOGY 85 (5), 2015Inclusion criteria for our meta-analysis were predetermined as
follows: (1) focus on human subjects, (2) hypospadias as primary
diagnosis, (3) exposure of patients to some form of hormonal
stimulation preoperatively, (4) performance of surgical repair,
(5) summarizing the number of cases with no response to
androgen stimulation, and (6) clinical research designation.
Individual studies that did not meet the aforementioned criteria
were excluded from this meta-analysis.Data Extraction
Data were independently extracted by 2 investigators (W.Z. and
J.Y.) and checked by other investigators for accuracy and
quality. Discrepancies were resolved by consensus after discus-
sions among investigators. Androgen insensitivity condition in
hypospadias was identiﬁed as no response to preoperative hor-
mone therapy. The related information was extracted from all
included publications and summarized in Table 1. When data
for a particular study were unclear or missing, we attempted to
contact the authors. Unfortunately, in some cases, we were
unable to obtain additional information.Assessment of Study Quality
The quality of individual studies was assessed independently by
2 investigators (W.Z. and J.Y.) using the standard criteria
adopted from the study by Jones et al,18 modiﬁed to ﬁt the
objectives of this study (Appendix). The 8-point scoring system
was based on factors that, we believed, would indicate the good
quality of observational studies. Study design, case number,
source of population, indication of hormone therapy, and
reporting of nonresponse cases were included in our evaluation
of the quality of included individual studies. Studies that
received an overall score of 6 were classiﬁed as high-quality
studies, those with an overall score of 3-5 were classiﬁed as
medium-quality studies, and those with an overall score of 2
were considered as low-quality studies for the purpose of this
analysis. These cut points were chosen according to the distri-
bution of relative quality scores of all included studies. Dis-
agreements were resolved through discussions with other
investigators.Statistical Analysis
Standard meta-analytic methods were used.18 We compared the
prevalence and variance in the random-effects model and in the
ﬁxed-effect model for aggregating individual effect sizes, aiming
to have the reliable conservative estimate. Forest plots were
generated showing the number of events, prevalence proportion
for each of the included studies, and corresponding 95% con-
ﬁdence interval (95% CI) for each study. For pooled data, the I2
index was calculated as a measure of the overall variation in
prevalence that was attributable to between-study heterogene-
ity. Percentages of the I2 index with I2 25%, 25% <I2 50%,
50% <I275%, or I2 75% were interpreted as low, medium,
above medium, and high heterogeneity, respectively. Publica-
tion bias was examined through the use of a funnel plot, and an
asymmetry in the funnel plot was tested by using the Egger
method.19 All analyses were conducted using R, version 3.1.1
for Windows, and graphics were generated (R Core Team
[2014]; R: A language and environment for statistical
computing; R Foundation for Statistical Computing, Vienna,
Austria, http://www.R-project.org/).1167
Table 1. Characteristics of included studies
Reference
No of
NR
No of
Cases
Penile
Measurement
Hormone
Used
Delivery
Route Hormone Dosage
Duration of
Treatment
Karyotyping
Abnormality Patients Selected Patient Age
Quality
Score
Snodgrass et al23 13 28 GW 15 mm T IM 2 mg/kg 2-3/mo 1 mo 2/9 cases Middle, 5; proximal, 23 Mean, 10 mo 3
Ishii et al20 0 17 PL T IM 25 mg 1/mo 3 mo 6/17 cases
(no AR
mutation)
Middle, 1; proximal, 16 1.4  1.3 y (0-5 y) 4
Nerli et al21 4 21 PL and GC T Topical
vs IM
2 mg/kg/wk 1/d
vs 2 mg/kg
1/mo
3 wks vs 3 mo N/S Middle, 10; proximal, 11 Mean, 19 mo
(16-27 mo)
3
Chalapathi et al7 1 25 PL T Topical
vs IM
2/d vs 2 mg/kg
1/wk
3 wks N/S Distal, 4; middle, 12;
proximal, 9
3.88 y (1-10 y) 4
Luo et al13 2 25 PL and GC T IM 25 mg 1/mo 3 mo N/S Middle, 8; proximal, 16 9-12 mo 2
Li et al25 2 27 PL T Topical 2/d 1 mo 0/13 cases N/S 3-9 y 3
Koff and Jayanthi12 0 12 PL HCG IM 250 IU 2/wk 5 wks N/S Middle, 7; proximal, 20 6-12 mo 1
Zhang and Sun26 2 35 PL HCG IM 1000 IU 2/wk 5-7.5 wks 0 Middle, 23; proximal, 12 1-7 y 2
Wang et al27 1 18 PL HCG IM 500-1000 IU
1/2-3 d
10-20 d 0 Proximal, 18 Mean, 4 y 3
Davits et al8 0 40 PL T IM 2 mg/kg 2 (ﬁrst
and fourth wks)
4 wks N/S N/S Mean, 27.3 mo
(13-74 mo)
3
Sakakibara et al22 0 15 Penile size T Topical Cycle, 0.2-0.4 g
1/d for 3 weeks
in a mo
Average 3 cycles
(1-10 cycles)
N/S Middle, 4; proximal, 11 Mean,
4.1 y (2.9-9.5 y)
3
Gearhart and Jeffs9 0 36 PL T IM 2 mg/kg 2/mo 1 mo N/S Distal, 4; middle, 23;
proximal, 3
N/S 1
Tsur et al24 0 7 PL T Topical 2/d 3 wks 1/7 cases
(47, XYY)
Distal, 3; middle, 2;
proximal, 2
Mean, 3.43 y (2-6 y) 3
AR, androgen receptor; GC, glans circumference; GW, glans width; HCG, human chorionic gonadotropin; IM, intramuscular; NR, nonresponder; N/S, nonspeciﬁed; PL, penile length; T, testosterone.
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Figure 1. Flow diagram of literature search and individual studies identiﬁed for this systematic review and meta-analysis.RESULTS
We initially identiﬁed 1278 potential relevant articles from
our search of published literatures (Fig. 1). After removing
duplicated records, we screened the remaining articles by
title and abstract reviews and obtained 38 publications for
further full-text investigations. Thirteen articles met all
inclusion criteria, and their prevalence estimates were
included in the overall meta-analysis.7-9,12,13,20-27 The
quality assessment of these individual studies based on the
standard criteria (Appendix) showed that 69% (9 of 13) of
these studies were of medium quality and 31% (4 of 13)
were of low quality. Detailed descriptions of individual
studies were summarized in Table 1.
These studies included 306 hypospadias patients
treated with preoperative hormone therapy. Of 13
studies, almost half (6 of 13) had no androgen resis-
tance, 2 had only 1 nonresponder, and 3 had only 2
nonresponders. Therefore, only 2 studies had >2 non-
responders. In fact, only 1 study provided 13 of the total
25 non-responders in this meta-analysis. Overall, 8.17%
(25 of 306) of hypospadias patients treated with preop-
erative hormone therapy showed androgen resistance.
The prevalence rates of androgen resistance in these 13UROLOGY 85 (5), 2015studies were ranged from 0% to 46%, with 95% CI from
0%-9% to 28%-66%.
Stringent overall prevalence was further investigated as
a weighted average of individual summary statistics. The
results were shown in the forest plot (Fig. 2). The
random-effects model provided a pooled estimate of
7.14% (95% CI, 3.16%-15.31%), whereas the ﬁxed-effect
model produced a pooled estimate of 14.61% (95% CI,
10.00%-20.85%).
The forest plot showed that 12 of the 13 studies pro-
vided similar estimates, whereas the study by Snodgrass
et al had a higher prevalence rate. Overall, heterogeneity
among the individual studies was found above medium
(I2 ¼ 67.1% [95% CI, 41.2%-81.6%]; P ¼ .0003).
However, after exclusion of the study by Snodgrass et al,
homogeneity among the remaining 12 studies was
observed (I2 ¼ 0% [95% CI, 0%-47.8%]; P ¼ .6421).
Further meta-analysis of these 12 studies showed that
both pooled estimates generated in random-effects model
and in ﬁxed-effect model were 6.95% (95% CI, 0%-
47.8%), consistent with those of the random-effects
model (7.14% [95% CI, 3.16%-15.31%]) calculated
from the analysis of all 13 studies, suggesting that the1169
Figure 2. Prevalence of androgen resistance in hypospadias patients treated with preoperative hormone therapy. Forest plot
shows number of events in total hypospadias cases and unadjusted prevalence estimate (square) with 95% conﬁdence in-
terval (bar) from individual studies. Weighted pooled prevalence estimates are represented as diamonds in this plot. CI,
conﬁdence interval.overall prevalence from the random-effects model may be
more accurate than that of the ﬁxed-effect model.
The funnel plot for these studies showed an asym-
metrical distribution of the individual studies (Fig. 3),
indicating a publication bias. Statistical analysis of these
data conﬁrmed the high signiﬁcance of publication bias
(Egger test t value ¼ 6.5039; degrees of freedom ¼ 11;
P ¼ 4.404e-05).COMMENT
Increasing number of studies reported androgen insensi-
tivity after preoperative hormone therapy, but the precise
extent of androgen resistance in hypospadias is obscure.
Gearhart and Jeffs9 described that 36.11% of hypospadias
patients (13 of 36) did not have a signiﬁcant increase in
penile length or circumference after the initial testos-
terone injection (2 mg/kg). However, after 2 doses,
phallic sizes of all patients were signiﬁcantly increased.
Ishii et al20 showed that the effect of testosterone enan-
thate treatment on the penile length for hypospadias
patients was signiﬁcantly less than that for micropenis
patients. Intriguingly, Snodgrass et al reported that as
high as 66.52% (19 of 29) of patients with proximal
hypospadias exhibited androgen resistance to certain
extent.23
This review and meta-analysis aimed to synthesize the
results from individual studies and deﬁne the frequency of
androgen insensitivity in hypospadias patients who
received hormone therapy preoperatively. Thirteen
studies were screened out from 1278 publications based
on predetermined criteria and showed weighted pooled
estimates of 7.14% in the random-effects model and117014.61% in the ﬁxed-effect model, respectively. About 2-
fold difference of the pooled prevalence observed in the 2
models may result from the heterogeneity of overall
variation in prevalence among all included studies as
revealed by the I2 index (67.1%; P ¼ .0003) and the
asymmetrical distribution of included individual studies
in the funnel plot (t value ¼ 6.5039; degrees of
freedom ¼ 11; P ¼ 4.404e-05). Perhaps, the study by
Snodgrass et al contributes to the heterogeneity as it had
a much higher prevalence rate. The high proportion of
proximal hypospadias patients (ie, 23 of 28) in the study
is apparently associated with the high frequency of
nonresponse or clinical androgen insensitivity (Table 1).
Indeed, after exclusion of the study by Snodgrass et al that
has an unusual estimate in the forest plot, the weighted
pooled estimate of 6.95% was obtained from both models,
consistent with the result in the random-effects model
calculated from all 13 studies. Thus, it appears that all
included 13 studies, even lack of sufﬁcient homogeneity,
are still comparable in the random-effects model that
appears to provide an accurate and convincing pooled
estimate in our meta-analysis.
Heterogeneity between individual studies suggests un-
derlying important differences in study design, patient
selection, hormone usage, dose regimens, routes of
administration, sample sizes, and outcome report of the
included eligible studies, all of which affect this meta-
analysis. Given the lack of standardizations on penile or
glans size for starting the therapy, drug selection, dose
regimens, and routes of administration in included
studies, it should be cautious to interpret the nonresponse
patients in many of these reports. Nevertheless, our sys-
tematic review and meta-analysis is the ﬁrst study toUROLOGY 85 (5), 2015
Figure 3. Funnel plot of included studies shows an asymmetrical distribution of the individual study and a publication bias
(Egger test t value ¼ 6.5039; degrees of freedom ¼ 11; P ¼ 4.404e-05).provide precise prevalence of androgen insensitivity after
preoperative hormone therapy.
To enhance the comparability across different indi-
vidual study, we only used categorical approaches rather
than dimensional approaches for our meta-analysis.
Perhaps, further subdivision of patient groups, for
example, distal hypospadias vs proximal hypospadias
would be more informative. However, limited studies to
date and limited sample sizes of the patients with pre-
operative hormone therapy in all included studies made it
impossible to realize such more stringent evaluation. To
enhance homogeneity of the samples, we were only able
to include nonresponse patients in different individual
studies, in which patients had different hypospadias
classiﬁcation and received different hormone treatment
and might not equally respond to the therapy. It was re-
ported that some patients did not response to testosterone
at all at the initial step of the treatment but afterward
exhibited much better response to testosterone.9,23 We
recommend that future studies on preoperative hormone
therapy in hypospadias should establish standardized
criteria, stratify patients based on hypospadias severity,
include large sample sizes, and randomize controlled
trials.
Considerable experience in patients with microphallus
suggests that short-term courses (3 months) of testos-
terone in modest amounts (25 mg intramuscular injection
every 4 weeks) were effective in promoting phallic growth
but did not appear to have an adverse effect on skeletalUROLOGY 85 (5), 2015growth.3,28 Therefore, we recommend it as a standardized
preoperative hormone therapy for hypospadias patients
with microphallus in future studies. Penile length should
be measured at least 4 weeks after the injections for
elevating androgenic responsiveness. The recommended
method for measuring penis is the stretched penile length.
In boys with hypospadias, measurement of the dorsal
aspect is the only way that can truly reﬂect potential
penile length.29 Nonresponse or clinical androgen
insensitivity should be deﬁned as no increase of penile
size or penile length after the standardized preoperative
hormone therapy.23
It should be noted that nonresponse to the preopera-
tive hormone therapy in those hypospadias patients might
partly be those patients with androgen insensitivity syn-
drome caused by the functional deﬁciency of androgen
receptor. Care needs to be individualized, ﬂexible, and
holistic.1 Management of androgen insensitivity patients
should address molecular, functional, sexual, and psy-
chological issues. Differential diagnosis of hypospadias
patients with androgen resistance from those with
androgen insensitivity syndrome would be important for
the patient management. It was reported that 3% of (9 of
292) isolated hypospadias boys had androgen receptor
missense mutations but did not show any phenotypic
difference to the vast majority of hypospadias boys.10
Some of such mutations may still retain their capacity
to bind ligand and respond to the treatment with supra-
physiological doses of androgen.30 Clearly, identiﬁcation1171
of the nature of mutations in the androgen receptor gene
in all hypospadias patients will be important in differen-
tial diagnosis but will also signiﬁcantly increase the costs.
Our ﬁndings suggest that preoperative hormone therapy
not only helps enlarge phallic size and consequently helps
simplify the surgical procedure but also helps identify the
patients with androgen insensitivity syndrome in a highly
focused way. To maximize the beneﬁts and minimize the
costs in the hypospadias management, we propose that
identiﬁcation of androgen receptor mutations in hypo-
spadias patients should speciﬁcally focus on those with
androgen resistance instead of all hypospadias patients.
Long-term follow-up of these patients is necessary to
determine whether these mutations cause signiﬁcant dif-
ferences in sexual function and fertility later in life.
Whether androgen insensitivity is an independent pre-
dictor of inferior outcome in hypospadias surgery needs
further investigations.
CONCLUSION
In this study, we have revealed that the prevalence of
androgen resistance in hypospadias patients is 7.14%
(95% CI, 3.16%-15.31%). Considering the lack of
response to hormone therapy may result from the patients
with androgen insensitivity syndrome, we recommend
that androgen resistant patients should be speciﬁcally
targeted by molecularly focused diagnosis, and manage-
ment strategies should include identiﬁcation of mutations
in the androgen receptor gene, timely surgery to repair
hypospadias, and long-term follow-up of sexual function
and fertility later in life. Randomized controlled trials,
standardized dosing protocols, mutational analysis of the
androgen receptor gene, and complete and consistent
reporting should be considered in future studies to deﬁne
the real accurate beneﬁt of preoperative hormone therapy
in hypospadias patients.
References
1. Hughes IA, Davies JD, Bunch TI, et al. Androgen insensitivity
syndrome. Lancet. 2012;380:1419-1428.
2. Ahmed SF, Achermann JC, Arlt W, et al. UK guidance on the
initial evaluation of an infant or an adolescent with a suspected
disorder of sex development. Clin Endocrinol (Oxf). 2011;75:12-26.
3. Hughes IA. Early management and gender assignment in disorders
of sexual differentiation. Endocr Dev. 2007;11:47-57.
4. Shih EM, Graham JM Jr. Review of genetic and environmental
factors leading to hypospadias. Eur J Med Genet. 2014;57:453-463.
5. Gorduza DB, Gay CL, de Mattos ESE, et al. Does androgen stim-
ulation prior to hypospadias surgery increase the rate of healing
complications? A preliminary report. J Pediatr Urol. 2011;7:158-161.
6. Netto JM, Ferrarez CE, Schindler Leal AA, et al. Hormone therapy
in hypospadias surgery: a systematic review. J Pediatr Urol. 2013;9:
971-979.
7. Chalapathi G, Rao KL, Chowdhary SK, et al. Testosterone therapy
in microphallic hypospadias: topical or parenteral? J Pediatr Surg.
2003;38:221-223.
8. Davits RJ, van den Aker ES, Scholtmeijer RJ, et al. Effect of
parenteral testosterone therapy on penile development in boys with
hypospadias. Br J Urol. 1993;71:593-595.
9. Gearhart JP, Jeffs RD. The use of parenteral testosterone therapy in
genital reconstructive surgery. J Urol. 1987;138:1077-1078.117210. Kalfa N, Philibert P, Werner R, et al. Minor hypospadias: the “tip of
the iceberg” of the partial androgen insensitivity syndrome. PLoS
One. 2013;8:e61824.
11. Kaya C, Bektic J, Radmayr C, et al. The efﬁcacy of dihy-
drotestosterone transdermal gel before primary hypospadias surgery:
a prospective, controlled, randomized study. J Urol. 2008;179:
684-688.
12. Koff SA, Jayanthi VR. Preoperative treatment with human chori-
onic gonadotropin in infancy decreases the severity of proximal
hypospadias and chordee. J Urol. 1999;162:1435-1439.
13. Luo CC, Lin JN, Chiu CH, et al. Use of parenteral testosterone
prior to hypospadias surgery. Pediatr Surg Int. 2003;19:82-84.
14. Monfort G, Lucas C. Dihydrotestosterone penile stimulation in
hypospadias surgery. Eur Urol. 1982;8:201-203.
15. Malik RD, Liu DB. Survey of pediatric urologists on the preopera-
tive use of testosterone in the surgical correction of hypospadias.
J Pediatr Urol. 2014;10:840-843.
16. Wright I, Cole E, Farrokhyar F, et al. Effect of preoperative hor-
monal stimulation on postoperative complication rates after prox-
imal hypospadias repair: a systematic review. J Urol. 2013;190:
652-659.
17. Gilliver SC, Ruckshanthi JP, Hardman MJ, et al. 5alpha-dihy-
drotestosterone (DHT) retards wound closure by inhibiting re-
epithelialization. J Pathol. 2009;217:73-82.
18. Jones L, Bellis MA, Wood S, et al. Prevalence and risk of violence
against children with disabilities: a systematic review and meta-
analysis of observational studies. Lancet. 2012;380:899-907.
19. Sterne JA, Egger M, Smith GD. Systematic reviews in health care:
investigating and dealing with publication and other biases in meta-
analysis. BMJ. 2001;323:101-105.
20. Ishii T, Hayashi M, Suwanai A, et al. The effect of intramus-
cular testosterone enanthate treatment on stretched penile
length in prepubertal boys with hypospadias. Urology. 2010;76:
97-100.
21. Nerli RB, Koura A, Prabha V, et al. Comparison of topical versus
parenteral testosterone in children with microphallic hypospadias.
Pediatr Surg Int. 2009;25:57-59.
22. Sakakibara N, Nonomura K, Koyanagi T, et al. Use of testosterone
ointment before hypospadias repair. Urol Int. 1991;47:40-43.
23. Snodgrass WT, Villanueva C, Granberg C, et al. Objective use of
testosterone reveals androgen insensitivity in patients with proximal
hypospadias. J Pediatr Urol. 2014;10:118-122.
24. Tsur H, Shaﬁr R, Shachar J, et al. Microphallic hypospadias:
testosterone therapy prior to surgical repair. Br J Plast Surg. 1983;36:
398-400.
25. Li X, Wei G, Lin T, He D. External use of androgen in treating
hypospadias with hypoplasia of penis in infants. Chin J Pract Pediatr.
2003;1:30-31; In Chinese.
26. Zhang F, Sun W. Use of chorionic gonadotropin in microphallic
hypospadias. Tianjin Pharm. 1998;10:52-53; In Chinese.
27. Wang G, Chen S, Jiang X. Endocrine studies and treatment in
patients with microphallic hypospadias. Chin J Pediatr Surg. 1995;
16:23-24; In Chinese.
28. Grino PB, Isidro-Gutierrez RF, Grifﬁn JE, et al. Androgen resistance
associated with a qualitative abnormality of the androgen receptor
and responsive to high dose androgen therapy. J Clin Endocrinol
Metab. 1989;68:578-584.
29. Fievet L, Harper L, Chirpaz E, et al. Penile length is comparable in
boys with and without hypospadias. J Pediatr Urol. 2012;8:493-496.
30. McPhaul MJ. Androgen receptor mutations and androgen insensi-
tivity. Mol Cell Endocrinol. 2002;198:61-67.APPENDIX
SUPPLEMENTARY DATA
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.urology.
2015.01.035.UROLOGY 85 (5), 2015
Appendix. Criteria for assessment of quality (maximum score = 8)* 
 
*Assessment instrument was adopted from Jones et al (2012) and modified to fit 
the objectives of this study. 
1.  Are the study design and sampling method appropriate for the research 
question? Random sample or whole population (1 point).  
2.  Is the sampling frame appropriate? Unbiased sampling frame (1 point).  
3.  Is the sample size adequate? Sample size greater than 100 individuals (1 
point).  
4.  Are objective, suitable, and standard criteria used for administration of 
preoperative hormone therapy? Official records or self-report with 
appropriate questions (1 point).  
5.  Are objective, suitable, and standard criteria used for measurement of 
penile size? (1 point).  
6.  Are cases of non-response reported? Non-responders described (1 point).  
7.  Are the estimates of prevalence given with confidence intervals (CIs)? CIs 
reported (1 point).  
8.  Are the study subjects and the setting described in detail? Study subjects 
described (1 point).  
